Krystal Biotech, Inc 8-K, filed Jun 1, 2020
Krystal Biotech, Inc. (KRYS)
About this 8-K
Krystal Biotech, Inc filed this 8-K on June 1, 2020, reporting on events of May 29, 2020.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENTREPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2020
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38210 | 82-1080209 |
|---|---|---|
| (State or other jurisdiction<br><br><br>of incorporation) | (Commission<br><br><br>File Number) | (IRS Employer<br><br><br>Identification Number) |
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (412) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17<br>CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br><br>Symbol(s) | Name of each exchange<br><br><br>on which registered |
|---|---|---|
| Common Stock | KRYS | Nasdaq |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders
At the Company’s annual meeting of stockholders held on May 29, 2020 the matters submitted to a vote of stockholders were (i) the election of two Class III directors to the Board of Directors for a term expiring at the 2023 annual stockholders meeting, and (ii) the ratification of the selection of Mayer Hoffman McCann P.C as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
The following table sets forth the results of voting for the election of the Class III directors to the Board of Directors:
| Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Krish Krishnan | 11,462,445 | 863,609 | 2,984,339 |
| Kirti Ganorkar | 11,476,518 | 849,536 | 2,984,339 |
The following table sets for the results of voting for the ratification of the appointment of Mayer Hoffman McCann P.C as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
| Votes For | Votes Against | Abstentions |
|---|---|---|
| 15,297,662 | 4,976 | 7,755 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 1, 2020 | KRYSTAL BIOTECH, INC. | |
|---|---|---|
| By: | /s/ Krish S. Krishnan | |
| Name: | Krish S. Krishnan | |
| Title: | President and Chief Executive Officer |